Levocarnitine.
Research-backed amino acid with potential health benefits. It's a transport system. Shuttles long-chain fatty acids into your mitochondria so they can be oxidized for energy. Crucial for heart, brain, and muscle function.
Reviewed March 2026
- Category
- Amino acid
What Levocarnitine is, and what it does.
- Does it work
- Maybe. For fat loss? Probably not. For male fertility, exercise recovery, or certain heart conditions? The evidence is much stronger. Depends entirely on why you're taking it.
- How much to take
- For exercise performance or recovery, 1-2 grams daily. For fertility or therapeutic uses, studies often use 2-3 grams. Always take with a meal, preferably with carbs.
- Time to feel it
- Give it three to four weeks of daily use. Muscle carnitine loads slowly, so recovery and training effects show up across weeks rather than inside a single session.
- The first dose
- Nothing. It needs to build up in your muscle tissue over days and weeks. This is a long-game supplement.
- With regular use
- After a few weeks of consistent use, athletes may notice reduced muscle soreness and better recovery. Benefits for things like fertility can take 3+ months to become apparent.
- How well tolerated
- Generally well tolerated. Stay under 3 grams daily to avoid potential gut issues or a 'fishy' body odor. If you have thyroid issues or seizures, talk to your doctor first.
- How it feels
- Quiet. No buzz and no lift. What people report over weeks is less soreness the day after hard training, and blood acylcarnitine profiles move before anything is felt.
- The overlooked benefit
- Its second job is housekeeping. It parks leftover acyl groups as acylcarnitines so free coenzyme A stays available for pyruvate dehydrogenase and the citric acid cycle.
500 to 2,000mg a day is where Levocarnitine works.
Source: Fielding 2018 + Ruggenenti 2009 kidney study
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Levocarnitine is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- Long-chain fatty acid transport into mitochondriaNarrative review
- Recovery and muscle soreness after trainingRandomised trial
- Physical performance and training capacityMeta-analysis
- Sperm motility and count markers in menMeta-analysis
- Body composition during a weight-loss phaseMeta-analysis
- Carnitine status on diets low in animal foodsCohort study
- Muscle function and walking capacity in older adultsRandomised trial
Questions people ask about Levocarnitine.
- Will it help me lose weight?
- Unlikely, unless you are truly deficient. The effect on fat loss in healthy people is minimal. Diet and exercise do the actual work.
- What's the best type? L-Carnitine vs Acetyl-L-Carnitine (ALCAR)?
- Depends on the goal. Standard L-Carnitine for physical performance and recovery. Acetyl-L-Carnitine (ALCAR) for brain health, as it crosses the blood-brain barrier.
- Should I take it with food?
- Yes, take it with carbs and protein. Insulin helps shuttle it into your muscles more effectively. An empty stomach can lead to nausea.
- Does it make you smell fishy?
- It can at high doses (3+ grams). It's a rare side effect caused by a metabolite (TMA). If it happens, lower the dose.
- Is it a stimulant?
- Nope. It's involved in energy production but won't give you a buzz or keep you awake like caffeine.
- Can I get it from food?
- Yes. Red meat is the best source, especially lamb and beef. Vegans get very little from their diet and may benefit most from supplementing.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Carnitine acetyltransferase moves acetyl groups on and off carnitine, so the two forms interconvert in the cell. ALCAR crosses into nervous tissue more readily while free carnitine dominates in muscle.
Carnitine carries long chain fatty acids into the mitochondrion and CoQ10 carries the electrons that beta oxidation releases. One supplies the fuel, the other moves the output.
The first oxidation step of every beta oxidation cycle uses an FAD dependent acyl-CoA dehydrogenase. Riboflavin status therefore sets how fast the fatty acids carnitine delivers are burned.
Carnitine exchanges acyl groups with coenzyme A on both sides of the mitochondrial membrane. Pantothenic acid is the precursor of that CoA pool.
Carnitine is built from methylated lysine residues released by protein turnover. Lysine supply sits at the start of that route.
Two of the four steps that build carnitine use ascorbate dependent dioxygenases. Low ascorbate slows endogenous carnitine formation.
The hydroxylases in carnitine biosynthesis are iron and 2-oxoglutarate dependent. Iron and ascorbate are required together at those steps.
Pyridoxal phosphate is required in the conversion route from trimethyllysine toward carnitine. B6 status affects how much carnitine the body makes on its own.
Lipoic acid is the cofactor of pyruvate dehydrogenase, the gate for carbohydrate derived fuel, while carnitine gates fat derived fuel. The pairing covers both entrances to the same cycle.
Each beta oxidation cycle reduces NAD to NADH. Niacin maintains the NAD pool that the fatty acids carnitine imports are oxidised against.
Gut bacteria convert both carnitine and choline into trimethylamine, which the liver oxidises to TMAO. Generous doses of both raise the same microbial metabolite from two directions.
Creatine buffers phosphate for short efforts while carnitine supports oxidative fat use over longer ones. They act on different energy systems in the same tissue.
Carnitine is built in the body from a lysine residue that has already been trimethylated, and every one of those three methyl groups comes from S-adenosylmethionine, which is made from methionine. Methionine supply therefore sits upstream of endogenous carnitine synthesis. This is settled biochemistry rather than a tested combination, so read it as mechanistic rather than clinical.
S-adenosylmethionine is the direct methyl donor for the trimethyllysine step that begins carnitine synthesis. Without adequate SAM the pathway stalls before the hydroxylation steps even start. The relationship is a biosynthetic dependency, not a demonstrated additive effect in people.
5-methyltetrahydrofolate donates the methyl group that regenerates methionine from homocysteine, refilling the pool that SAM draws on for carnitine methylation. Folate status therefore sits two steps upstream of carnitine biosynthesis. The link is metabolic, and no combination trial is being cited for it.
Methionine synthase needs cobalamin to move the folate methyl group onto homocysteine, which is how the methionine and SAM pools are maintained. B12 also runs methylmalonyl-CoA mutase, the step that clears propionyl residues that carnitine helps buffer as acylcarnitines. Both connections are textbook cofactor relationships.
Betaine remethylates homocysteine through betaine-homocysteine methyltransferase, a folate-independent route to methionine and then to SAM. That spares methionine for the trimethylation that carnitine synthesis needs. The overlap is at the methyl-supply level rather than at carnitine itself.
Long-chain fatty acids cannot cross the inner mitochondrial membrane as acyl-CoA; carnitine palmitoyltransferase 1 hands them to carnitine and the acylcarnitine is shuttled across. EPA and DHA are long-chain fatty acids and use that same door. The pairing is a substrate-carrier relationship, so it describes handling rather than any clinical outcome.
Medium-chain fatty acids diffuse into mitochondria and are activated inside, bypassing the carnitine shuttle almost entirely. So MCT does not compete with carnitine and does not depend on it either. Formulators sometimes pair them for that contrast, and the honest description is independence rather than synergy.
Endogenous carnitine synthesis starts from protein-bound lysine and needs methionine-derived methyl groups, and whey supplies both amino acids in quantity. Dietary protein intake is one input to the endogenous pool alongside preformed dietary carnitine. The claim is about substrate supply, not about any measured increase in tissue carnitine from the pairing.
Gut bacteria convert a fraction of unabsorbed carnitine to trimethylamine, which the liver then oxidises to trimethylamine N-oxide. The size of that fraction tracks with which organisms are present, so the microbial community modulates how much ingested carnitine goes down that route. TMAO is a circulating marker, not an outcome, and the direction of any clinical meaning is contested.
Taurine and carnitine are both concentrated in cardiac and skeletal muscle and both are handled by sodium-dependent transporters of the SLC family. Their roles differ: carnitine moves acyl groups, taurine works on osmotic and calcium handling. The pairing is conventional in formulations and rests on tissue overlap rather than on a combination study.
Ribose feeds the pentose phosphate route toward adenine nucleotide resynthesis while carnitine governs fatty-acid entry to beta-oxidation. Both sit on the supply side of cellular energy turnover but at different steps. Nothing here is a tested combination and the confidence label reflects that.
Each round of beta-oxidation reduces NAD+ to NADH, so the pathway carnitine feeds is NAD-dependent throughout. NR raises NAD+ precursor availability. The connection is stoichiometric logic rather than a demonstrated pairing effect.
Caffeine raises circulating free fatty acids through lipolysis, and carnitine governs whether those fatty acids enter mitochondria. The two act at different points of the same supply line. This is a mechanistic rationale for a common pre-workout pairing, not a measured combination result.
Nothing specific on file for Levocarnitine. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Levocarnitine actually does.
Carnitine carries long-chain fatty acids across the inner mitochondrial membrane. Carnitine palmitoyltransferase 1 transfers the acyl group from CoA to carnitine, the carnitine-acylcarnitine translocase moves the acylcarnitine across, and CPT2 hands the acyl group back to CoA inside the matrix so beta-oxidation can begin.
Carnitine buffers the mitochondrial acyl-CoA to free CoA ratio. Excess acyl groups are parked as acylcarnitines and exported, which keeps free coenzyme A available for pyruvate dehydrogenase and the citric acid cycle.
Endogenous synthesis runs from protein-bound trimethyllysine through gamma-butyrobetaine to carnitine, and needs vitamin C for the two hydroxylation steps, plus iron, niacin-derived NAD and vitamin B6 across the pathway.
OCTN2 (SLC22A5) is the sodium-dependent transporter that takes carnitine into tissue and reabsorbs it in the kidney tubule, which is why plasma concentrations are held within a narrow range and renal handling dominates clearance.
Where Levocarnitine comes from.
It is made in a factory, not pulled out of meat. Two routes are used: a chemical one and a bacterial fermentation one, and both finish with purification steps that confirm the material is the L form your cells actually use.
The same molecule is reached more than one way. Which route a given product used is a manufacturing choice, and the finished compound is the same either way.
Chemical routes start from epichlorohydrin and trimethylamine with a cyanide or crotonobetaine intermediate; biotechnological routes start from crotonobetaine or gamma-butyrobetaine fed to a bacterial culture.
Chemical routes resolve or asymmetrically induce the L configuration; microbial routes rely on a bacterial hydratase or hydroxylase that produces only the L enantiomer, which is what makes fermentation attractive for chirality.
The broth or reaction mixture is clarified, passed over ion-exchange resin, decolourised and crystallised, then dried to a free-flowing solid.
Assay by titration or HPLC, optical rotation or chiral chromatography to confirm the L enantiomer, plus residual solvent and heavy metal limits.
The base is either filled as a solution, or reacted with L-tartaric acid and crystallised to the tartrate for dry dosage forms.
Manufacturers rarely state on the label which of the two routes produced a given lot.
Getting Levocarnitine from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- The authors pooled controlled trials and reported fewer drops in blood pressure during sessions among supplemented participants, with the caveat of small and heterogeneous studies.Meta-analysis. Chewcharat A et al., 2022 (PLoS One). PMID 35834513 ↗
- The reviewers pooled paediatric studies adding levocarnitine to conventional care and reported ejection fraction, an imaging marker rather than a clinical endpoint.Systematic review. Wang Y et al., 2018 (Paediatric Drugs). PMID 29468383 ↗
- Myocardial strain on echocardiography was tracked in supplemented children; strain is an imaging marker, and the design cannot establish cause.Cohort study. Sgambat K et al., 2021 (Pediatric Nephrology). PMID 33389092 ↗
- A clinical-practice report of levocarnitine use alongside intravenous nutrition, following serum triglyceride concentrations as the measured marker.Cohort study. Grucz TM et al., 2022 (Nutrition in Clinical Practice). PMID 34528297 ↗
- The authors describe liver enzyme trajectories in adults given levocarnitine during asparaginase-containing therapy; a descriptive series with no control group.Case series. Defina M et al., 2022 (Leukemia Research). PMID 36155352 ↗
- Retrospective comparison of muscle mass indices between supplemented and unsupplemented patients on lenvatinib; an association in a non-randomised group.Cohort study. Okubo H et al., 2021 (Nutrients). PMID 34959980 ↗
- A phase 2a study measuring muscle strength and fatigue scales in children with an inherited genetic condition; feasibility and signal-seeking rather than confirmatory.Open-label trial. Vasiljevski ER et al., 2021 (American Journal of Medical Genetics Part A). PMID 34155781 ↗
- Kidney function was the main determinant of carnitine clearance after high-dose intravenous dosing; a pharmacokinetic finding, not an efficacy result.Cohort study. Jennaro TS et al., 2023 (Pharmacotherapy). PMID 37775945 ↗
- A formulation case study describing how levocarnitine is prepared for paediatric dosing, including palatability, excipient and stability constraints.Narrative review. Tomlin S et al., 2026 (Pharmaceutical Medicine). PMID 42243603 ↗
- Case descriptions with a literature review of a rare metabolic enzyme deficiency in which carnitine is named among the management measures reported.Case series. Monda E et al., 2023 (European Journal of Medical Genetics). PMID 37979716 ↗
- A review of preventive interventions during anthracycline-based chemotherapy that names levocarnitine among the agents assessed; a mention within a broader comparison.Systematic review. Liu X et al., 2025 (Frontiers in Cardiovascular Medicine). PMID 40970189 ↗
These are the studies our verdict leans on, chosen from the 11 we read for Levocarnitine. The full linked list is below.
The studies, linked.
3 sources behind our Levocarnitine verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialPhase III Randomized Placebo-Controlled Trial to Determine Efficacy of Levocarnitine for Fatigue in Patients With CancerClinicalTrials.gov ↗PHASE3 · 376 participants · Completed
- Clinical trialMitochondrial Cofactors for the Treatment of Hyperbilirubinemia Due to PEG-Asparaginase and or Inotuzumab Ozogamicin in Patients With Acute Lymphoblastic Leukemia (ALL)ClinicalTrials.gov ↗PHASE2 · 10 participants · Terminated
- Clinical trialOral L-Carnitine Supplementation in Cardiorenal Heart Failure PatientsClinicalTrials.gov ↗EARLY PHASE1 · 20 participants · Recruiting
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Problems people have reported.
Read this carefully. These are 8,261 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Levocarnitine is, not how risky it is. A report is not proof Levocarnitine caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.